Table 1.
Abbreviated Summary of CPIC Guidelines*
| Medication | Relevant Gene(s) | Reason |
|---|---|---|
| Analgesics | ||
| Codeine | CYP2D6 | Lack of analgesia |
| Anticancer Agents | ||
| Capecitabine | DPYD | Risk of fatal toxicity/dose selection |
| Fluorouracil | DPYD | Risk of fatal toxicity/dose selection |
| 6-mercaptopurine | TPMT | Inefficacy and risk of fatal toxicity |
| Tegafur | DPYD | Risk of fatal toxicity/dose selection |
| Thioguanine | TPMT | Inefficacy and risk of fatal toxicity |
| Anticoagulant | ||
| Warfarin | CYP2C19, CYP2D6 | Inefficacy and starting dose selection |
| Antidepressants | ||
| Amitriptyline | CYP2C19, CYP2D6 | Dose and therapy selection |
| Citalopram | CYP2C19 | Dose and therapy selection |
| Clomipramine | CYP2C19, CYP2D6 | Dose and therapy selection |
| Desipramine | CYP2D6 | Dose and therapy selection |
| Doxepin | CYP2C19, CYP2D6 | Dose and therapy selection |
| Escitalopram | CYP2C19 | Dose and therapy selection |
| Fluvoxamine | CYP2D6 | Dose and therapy selection |
| Imipramine | CYP2C19, CYP2D6 | Dose and therapy selection |
| Nortriptyline | CYP2D6 | Dose and therapy selection |
| Paroxitine | CYP2D6 | Dose and therapy selection |
| Sertraline | CYP2C19 | Dose and therapy selection |
| Trimipramine | CYP2C19, CYP2D6 | Dose and therapy selection |
| Antiemetics | ||
| Ondansetron | CYP2D6 | Therapy selection |
| Tropisetron | CYP2D6 | Therapy selection |
| Antifungal | ||
| Vorconazole | CYP2C19 | Therapy selection |
| Antiplatelet | ||
| Clopidogrel | CYP2C19 | Dose and therapy selection |
| Antiseizure | ||
| Carbamazepine | HLA-B | SCAR |
| Phenytoin | CYP2C9, HLA-B | Starting dose selection |
| Cystic Fibrosis | ||
| Transporter Potentiator | ||
| Ivacaftor | CFTR | Therapy selection |
| Xanthane Oxidase Inhibitor | ||
| Allopurinol | HLA-B | Risk of SCAR |
| Antivirals | ||
| Ribavirin | IFNL3 | Poor response rates |
| Peginterferon-α2a | IFNL3 | Poor response rates |
| Peginterferon-α2b | IFNL3 | Poor response rates |
| Antiretrovirals | ||
| Abacavir | HLA-B | SCAR |
| Atazanavir | UGT1A1 | Bilirubin-related discontinuation |
| Immunosuppressants | ||
| Azathioprine | TPMT | Risk of fatal toxicity |
| Tacrolimus | CYP3A5 | Dose selection |
| Statin | ||
| Simvastatin | SLCO1B1 | Dose or alternative statin selection |
| Uric Acid Metabolizer | ||
| Rasburicase | G6PD | Risk of hemolytic anemia |
*
All data available on Pharmgkb.org